136 related articles for article (PubMed ID: 21235090)
21. The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.
Slamon DJ
Oncologist; 2004; 9 Suppl 3():1-3. PubMed ID: 15163840
[No Abstract] [Full Text] [Related]
22. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S
Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
[TBL] [Abstract][Full Text] [Related]
23. [Her2/neu receptor: one of the basic factors rendering tailored therapy feasible in breast cancer patients].
Kulka J
Orv Hetil; 2005 Apr; 146(17):785-90. PubMed ID: 17918634
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab--mechanism of action and use.
Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
N Engl J Med; 2007 Oct; 357(16):1664; author reply 1665-6. PubMed ID: 17942884
[No Abstract] [Full Text] [Related]
25. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; dei Tos AP; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M
Clin Breast Cancer; 2008 Oct; 8(5):436-42. PubMed ID: 18952558
[TBL] [Abstract][Full Text] [Related]
26. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
Guarneri V; Barbieri E; Dieci MV; Piacentini F; Conte P
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S62-6. PubMed ID: 21129613
[TBL] [Abstract][Full Text] [Related]
27. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease.
Ferretti G; Fabi A; Felici A; Papaldo P
J Clin Oncol; 2010 Jul; 28(20):e337; author reply e338-9. PubMed ID: 20479395
[No Abstract] [Full Text] [Related]
28. Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls.
Brandes AA; Franceschi E; Tosoni A; Degli Esposti R
Expert Rev Anticancer Ther; 2010 Feb; 10(2):179-84. PubMed ID: 20131994
[TBL] [Abstract][Full Text] [Related]
29. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
Tokuda Y; Suzuki Y; Saito Y; Umemura S
Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
[TBL] [Abstract][Full Text] [Related]
30. [Novel target therapies used in breast cancer management].
Semiglazova TIu; Semiglazov VV; Filatova LV; Gershanovich ML; Chudenko VA; Latipova DKh; Luk'ianchikova VS; Dashian GA; Paltuev RM
Vopr Onkol; 2011; 57(5):592-600. PubMed ID: 22238928
[No Abstract] [Full Text] [Related]
31. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
32. [Resistant mechanisms against breast cancer treatment and therapeutic strategies].
Tanizaki J; Tsurutani J
Nihon Rinsho; 2012 Nov; 70 Suppl 8():336-40. PubMed ID: 23513862
[No Abstract] [Full Text] [Related]
33. HER2 as a target for breast cancer therapy.
Tagliabue E; Balsari A; Campiglio M; Pupa SM
Expert Opin Biol Ther; 2010 May; 10(5):711-24. PubMed ID: 20214497
[TBL] [Abstract][Full Text] [Related]
34. [Breast cancer and Her-2].
Hatake K
Nihon Rinsho; 2007 Jun; 65 Suppl 6():87-94. PubMed ID: 17682144
[No Abstract] [Full Text] [Related]
35. Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer.
Suzuki Y; Saito Y; Terao M; Terada M; Morioka T; Tsuda B; Okamura T; Niikura N; Tokuda Y
Tokai J Exp Clin Med; 2010 Dec; 35(4):148-51. PubMed ID: 21319046
[TBL] [Abstract][Full Text] [Related]
36. Targeted Therapies in the Treatment of Breast Cancer. Proceedings of a meeting. Kailua-Kona, Hawaii, July 19-23, 2000.
Semin Oncol; 2001 Oct; 28(5 Suppl 16):1-153; quiz 154-65. PubMed ID: 11760720
[No Abstract] [Full Text] [Related]
37. Trastuzumab--mechanism of action and use in clinical practice.
Hudis CA
N Engl J Med; 2007 Jul; 357(1):39-51. PubMed ID: 17611206
[No Abstract] [Full Text] [Related]
38. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
Mallmann P
Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
[No Abstract] [Full Text] [Related]
39. Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing.
Baselga J
Ann Oncol; 2002 Jan; 13(1):8-9. PubMed ID: 11863116
[No Abstract] [Full Text] [Related]
40. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.
Hortobagyi GN
Semin Oncol; 2001 Dec; 28(6 Suppl 18):43-7. PubMed ID: 11774205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
